(J Clin Gastroenterol 2017;51:508-511) P atients with Crohn's disease (CD) often require surgery. As many as 55% of patients with CD undergo surgery in the first 10 years after diagnosis and up to 35% require a second surgery in the subsequent 10 to 15 years. 1 Overall 9% to 13% of CD patients require 2 or more surgeries. 2, 3 In the age of biological therapy, stricturing disease is one of the more common indications for intestinal resections in CD. Most primary intestinal resections involve the ileocecal region and require only a short-segment resection. A small group of patients require multiple resections resulting in short bowel syndrome (SBS)-associated intestinal failure and require parenteral support. 4, 5 Glucagon-like peptide 2 (GLP-2) is a 33-amino acid peptide, involved in the normal growth and maintenance of the intestinal epithelium. The secretion of GLP-2 by enteroendocrine cells, located primarily in the terminal ileum and colon, is stimulated by the presence of nutrients. 6 GLP-2 has been shown to slow gastric emptying, decrease gastric secretions, and increase the intestinal blood flow, stimulating growth of the large and small intestine. [7] [8] [9] [10] [11] [12] [13] The half-life of GLP-2 is only 7 minutes. Substituting glycine for alanine extends the half-life to 3 hours, which makes the GLP-2 analogue, teduglutide, an attractive therapeutic agent. 14, 15 Teduglutide was given orphan drug status for SBS by the Food and Drug Administration in 2000. It was approved in 2012 for the treatment of adult patients with SBS who are dependent on parenteral support. This approval was based on 2 placebo-controlled trials over 24 weeks of 169 patients treated with teduglutide (either 0.05 or 0.1 mg/kg) or placebo. 16, 17 In addition, data are available from a 28-week double-blind extension study of one of the previous 24-week studies, in which 52 patients were either treated with 0.05 or 0.1 mg/kg bodyweight or placebo. 18 In these studies, 36% and 21% of patients had CD. However, in all of these studies, concomitant therapy with biological agents or immunomodulators was an exclusion criterion. As clinical trials, especially in the field of inflammatory bowel diseases, are not representative of clinical practice, 19 IBD providers are cautious in the use of this novel medication in CD patients.
To date, there are no real-world safety and efficacy reports available of teduglutide in CD patients with SBS requiring parenteral support, especially those who are treated with biological agents. Therefore, we retrospectively evaluated a cohort of patients with CD treated with teduglutide in 3 tertiary care centers in the United States to evaluate the safety and efficacy of teduglutide.
METHODS
We conducted a retrospective cohort study at the University of North Carolina, Massachusetts General Hospital, and Boston Medical Center. The institutional review boards of all 3 institutions approved the study protocol. Chart reviews identified all patients between 2007 and 2014 with CD and SBS treated with teduglutide therapy. Demographic, clinical, surgical, and therapeutic data were retrieved from the electronic medical record systems. Past and current medications (defined in relation to teduglutide therapy) for CD were evaluated. In addition, the need for parenteral support before and during therapy with teduglutide was calculated.
Statistical Analysis
We used descriptive statistics to summarize the characteristics of all patients. Continuous variables are reported as median with interquartile range (IQR), and categorical variables are reported as percentages. Analyses were performed using Stata 10.0 (College Station, TX).
RESULTS
We identified 13 CD patients on teduglutide therapy (Table 1 ). All patients were started on the recommended dose of 0.05 mg/kg/d. Eight patients (61.5%) were treated with concomitant immunosuppressive therapy. The median duration of teduglutide therapy was 365 days (IQR, 122 to 482 d) and 9 patients (69.2%) remain on teduglutide therapy at the conclusion of follow-up. Duration of follow-up ranged from 3 to 22 months with a median of 14 months. The median body weight increase was 3 kg (IQR, 0 to 6 kg), which was a median increase of 3.8% of total body weight. The median increase in the body mass index was 1.9 (IQR, À0.6 to 2.4).
Parenteral Support
Nine of the 13 patients (69.2%) were on parenteral nutrition at the initiation of teduglutide therapy. Only 1 patient (7.7%) was on parenteral nutrition at the conclusion of follow-up ( Fig. 1 ). All patients were on intravenous fluid support at the start of therapy, with a median of 9000 mL/wk (IQR, 7000 to 14,000 mL). Fluid volume requirements decreased during the course of observation by a median of 3100 mL/wk (IQR, 2400 to 8400 mL/wk). Six patients (46%) did not require any intravenous fluids at the conclusion of follow-up. Two patients stopped teduglutide due to stable nutritional status without the need for parenteral support after 14 and 23 months of therapy.
Adverse Events
Adverse events that may have been associated with the teduglutide included pancreatitis (n = 1), asymptomatic elevation of lipase and amylase (n = 1), and abdominal pain (n = 2); these were all in patients on concomitant immunosuppression (Table 2) . One patient, not on immunosuppression, reported nausea. Another patient, not on immunosuppression, developed intermittent obstructive symptoms, necessitating teduglutide cessation. Three patients on concomitant immunosuppression experienced infectious line complications compared with 1 patient on no concomitant immunosuppression.
DISCUSSION
This is the first real-world experience describing the safety and effectiveness of teduglutide in CD patients, including those on immunosuppression, with SBS-associated intestinal failure requiring parenteral support. Other than 2 placebo-controlled trials, which only included a small number of CD patients, there are no published reports about the use of teduglutide in patients with CDassociated SBS. Furthermore, in all prospective studies of teduglutide, patients were not treated with concomitant immunosuppressive therapies. Thus, our cohort presents new and relevant information on the efficacy and safety of teduglutide in practice beyond clinical trials. The strict pathophysiological definition of short bowel-associated intestinal failure, small bowel length <200 cm, is no longer clinically relevant because it does not reflect the absorptive capacities of the remaining bowel. 20 The colon, which conserves fluid, electrolytes, and salvages malabsorbed carbohydrate and protein, at least partially compensates for resected small bowel. 21 Thus, even limited resections with a consecutive ileostomy can result in SBS, requiring parenteral support.
In our cohort, teduglutide was highly effective in reducing the need for parenteral support. Our results are consistent with the only other report of treatment outcomes in teduglutide. However, that was in a case series of 6 patients without CD who have SBS. 22 In this series, parenteral support could be reduced by at least 20% in all patients and completely discontinued in 4/6 patients (67%). In our cohort, parenteral support was reduced in 100% of patients and completely discontinued in 6/13 (46%) of patients. This case series and our cohort found the ability to decrease and discontinue parenteral support to be higher than reported in the 52-week prospective trial. 18 Overall, teduglutide seemed to be safe and well tolerated in our cohort. The most common adverse events observed in the prospective trials of teduglutide were headache, abdominal pain, nausea, nasopharyngitis, vomiting, and catheter sepsis. [16] [17] [18] 23 Nausea and/or vomiting seemed to be dose related, occurring in approximately 20% of CD patients treated with 0.05 mg/kg daily and increased to nearly 40% with the highest dose of 0.2 mg/kg daily. 24 This is likely due to the effects of teduglutide on gastric emptying and motility. 25, 26 Abdominal pain and nausea were the most common side effects observed in our study. However, none of the patients had to stop therapy due to these side effects. Catheter-associated sepsis, which we observed in 4 patients, is most likely because all these patients have permanent intravenous catheters, which by itself is a risk for catheter sepsis. 27, 28 Teduglutide can cause congestive heart failure due to improved absorption of fluids 29 ; however, this was not observed in our small cohort.
Another adverse event of concern is bowel obstruction. In patients with stricturing CD, bowel obstruction is due to the trophic effects of teduglutide with the increase in size and density of the intestinal villi. One patient in the 52-week teduglutide treatment trial experienced acute intestinal obstruction, which resolved after teduglutide discontinuation. In our cohort, over 50% of patients had a history of stricturing CD. One patient, not on concomitant immunosuppression, developed obstructive episodes, which resolved after teduglutide was reduced to every-other-day therapy. An increase in the size of ileostomies was also reported. Given the retrospective nature of the study, it was not possible to assess the increase in ostomy size in our cohort.
There is also a risk of neoplastic proliferation in the intestine with teduglutide, which, as in the clinical trials, was not observed in our small cohort. 23, 30 However, the average follow-up time of 1 year, both in our cohort and the clinical trials, is short. Long-term observations, such in the prospective, multicenter registry for patients with SBS, are necessary to adequately assess the safety and efficacy of teduglutide. 31 Teduglutide was also evaluated in a prospective placebo-controlled study for the treatment of moderate to severe CD. Three different doses of teduglutide, 0.05, 0.10, and 0.2 mg/kg daily, were compared with placebo in an 8-week trial. This was followed by an open-label 12-week extension trial. 24 There were no significant differences in response and remission for all 3 teduglutide doses compared with placebo after 8 weeks. Circulating citrulline, an end product of the glutamine metabolism, is a solely product of enterocytes and a proposed biomarker for the small bowel absorptive area and function. 32 Plasma citrulline increased significantly at week 2, 4, and 8 in all 3 teduglutide groups, supporting the biological activity of teduglutide.
Given the need for long-term therapy with teduglutide, it will become important to determine whether there is a risk of developing neutralizing antibodies, which might be decreased by immunosuppressive therapy. Currently, there are no commercial assays to measure antibodies to teduglutide. In the prospective trials, 6/43 (14%) and 14/52 (27%) of patients had detectable non-neutralizing antibodies after 24 and 52 weeks of therapy, respectively. Similarly, it is not known whether a drug holiday or cessation in patients with successful teduglutide therapy is warranted or whether this would result in the need to restart parenteral support. In our cohort, 2 patients had teduglutide therapy stopped after remaining completely off parenteral support for several months. Both had some part of their colon in place; this may be a positive predictor for stability off teduglutide once the parenteral support is weaned off. 33 There are limitations to our study. The small number of patients in our cohort is reflective of how rarely either CD and SBS coincide or how infrequently teduglutide is used in CD patients even in tertiary-care institutions across the United States. Its use may be significantly hampered by the expense of therapy ($295,000 per year) and difficulty of insurance approval. Other reasons for the small number of patients may be due to provider concerns of adverse events especially in combination with immunosuppression. The retrospective nature of the study resulted in limitations to the information available for the subjects. Because of the small number of patients and short duration of follow-up, we are also not able to address the long-term durability or effects of teduglutide therapy. It also remains unknown whether concomitant immunotherapy has a protective effect on the clinical efficacy of teduglutide. We were also unable to determine the length of remaining small bowel in the individual patients because patients underwent multiple surgeries at various institutions. However, as discussed, the current classification of intestinal failure in the setting of 
